Study on the Effect of Irbesartan on Atrial Fibrillation Recurrence in Kumamoto: AF Suppression Trial
Not Applicable
- Conditions
- Atrial Fibrillation and Hypertention
- Registration Number
- JPRN-UMIN000005205
- Lead Sponsor
- Kumamoto University School of Medicine University Hospital, Department of Cardiac Arrhythmias
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 154
Inclusion Criteria
Not provided
Exclusion Criteria
Key exclusion criteria Patients were excluded from the study on the basis of the following criteria: contraindications to treatment with irbesartan or amlodipine; myocardial infarction during the previous 3 months; cardiac surgery during the previous 3 months; bradycardia<50 bpm while the patient was awake; unstable angina: NYHA heart failure class not less than III: QT interval not less than 480 ms in the absence of bundle-branch block; significant impairment of renal function: significant hepatic disease.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method